Zibor 25,000 IU anti-Xa/ml solution for injection in pre-filled syringes Ireland - English - HPRA (Health Products Regulatory Authority)

zibor 25,000 iu anti-xa/ml solution for injection in pre-filled syringes

rovi pharma industrial services s.a. - bemiparin sodium - solution for injection in pre-filled syringe - 25,000 international unit(s) - heparin group; bemiparin

Zibor 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringes Ireland - English - HPRA (Health Products Regulatory Authority)

zibor 2,500 iu anti xa/0.2 ml solution for injection in pre-filled syringes

rovi pharma industrial services s.a. - bemiparin sodium - solution for injection in pre-filled syringe - 2,500 iu international unit(s) - bemiparin

Zibor 3,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringes Ireland - English - HPRA (Health Products Regulatory Authority)

zibor 3,500 iu anti xa/0.2 ml solution for injection in pre-filled syringes

rovi pharma industrial services s.a. - bemiparin sodium - solution for injection in pre-filled syringe - 3,500 iu international unit(s) - bemiparin

CRUSIA Israel - English - Ministry of Health

crusia

tzamal bio-pharma ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg / 1 ml - enoxaparin - crusia is indicated in adults for:•prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.•prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.•treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe ikely to require thrombolytic therapy or surgery. prevention of thrombus formation in extra corporeal circulation during haemodialysis.•acute coronary syndrome:-treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid.-treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).